Practical Strategies for SCIg Maintenance Therapy in CIDP Patients

This clinical research article investigates the effectiveness and practical management of subcutaneous immunoglobulin (SCIg) as a maintenance therapy for individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). By analyzing twenty retrospective cases from various U.S. medical centers, the authors explore the transition process from intravenous to subcutaneous administration, focusing on individualized dosing strategies. The study reveals that most patients successfully maintained clinical stability after switching, often citing improved convenience and site-of-care flexibility as primary motivations. Results indicate that while a one-to-one dosing ratio is a common starting point, many patients require customized adjustments to prevent relapses or achieve the lowest effective dose. Ultimately, the research emphasizes the importance of shared decision-making and ongoing monitoring to optimize long-term outcomes and treatment tolerability.